Table 1.

Active clinical trials listed on clinicaltrails.gov (as of Oct 2020) involvingMEK inhibitors, for which NF1-related indications are eligible. This list is organized by NF1 focus. cNF cutaneous neurofibroma, HGG high-grade glioma, JMML juvenile myelomonocytic leukemia, LGG low-grade glioma, MPNST malignant peripheral nerve sheath tumor, OPG optic pathway glioma, pNF plexiform neurofibroma

Trial identifier	Drug(s)	Indication	Phase	Population	NF specific focus
NCT03433183	Selumetinib, sirolimus	MPNST	II	≥12 years	Yes
NCT03962543	Mirdametinib	Inoperable pNF	II	≥2 years	Yes
NCT03190915	Trametinib	Relapsed/refractory JMML	II	≥1 months	Yes
NCT02124772	Trametinib	Refractory pNF	I/II	≥1 month to ≤17 years	Yes
NCT03326388	Selumetinib	Inoperable pNF, progressive OPG	I/II	≥3 years to ≤18 years	Yes
NCT03231306	Binimetinib	Symptomatic pNF	II	≥1 years	Yes
NCT01089101	Selumetinib	Relapsed/refractory LGG	I/II	≥3 to ≤21 years	Yes
NCT02839720	Selumetinib	Symptomatic cNF	II	≥18 years	Yes
NCT02285439	Binimetinib	Advanced solid tumors and relapsed/refractory LGG	I/II	≥1 to ≤18 years	Yes
NCT04201457	Trametinib, dabrafenib, hydroxychloroquine	Recurrent LGG or HGG	I/II	≥1 to ≤30 years	Yes
NCT02407405	Selumetinib	Inoperable pNF	II	≥18 years	Yes
NCT04435665	NFX-179 (topical)	cNF	II	≥18 years	Yes
NCT03741101	Trametinib	pNF	II	≥1 to <18 years	Yes
NCT03871257	Selumetinib	NF1-associated LGG	III	≥2 to ≤21 years	Yes
NCT03363217	Trametinib	pNF and relapsed/refractory LGG	I/II	≥1 month to ≤25 years	Yes
NCT04216953	Cobimetinib, atezolizumab	Advanced soft tissue sarcoma	I/II	≥6 months	No
NCT03516123	CS3006	Advanced solid tumors	I	≥18 years	No
NCT03875820	RO5126766, VS-6063	Advanced solid tumors	I	≥18 years	No
NCT03905148	Mirdametinib, BGB-283	Advanced solid tumors	I	≥18 years	No
NCT02079740	Trametinib, navitoclax	Advanced solid tumors	I/II	≥18 years	No
NCT01364051	Selumetinib, cediranib	Advanced solid tumors	I	≥18 years	No
NCT03736850	CS3006	Advanced solid tumors	I	≥18 years	No
NCT03976050	HL-085	Advanced solid tumors	I	≥18 years	No
NCT01586624	Selumetinib, vandetanib	Advanced solid tumors	I	≥18 years	No
NCT03839342	Binimetinib, encorafenib	Advanced solid tumors	II	≥18 years	No
NCT02070549	Trametinib	Advanced solid tumors	I	≥18 years	No
NCT04485559	Trametinib, everolimus	Relapsed/refractory LGG		≥1 to ≤25 years	No
NCT03108131	Cobimetinib, atezolizumab	Advanced solid tumors	II	≥18 years	No
NCT03434262	Trametinib, ribociclib (stratum B)	Recurrent/refractory HGG	I	≥1 to ≤39 years	No
NCT01827384	Trametinib	Advanced solid tumors	II	≥18 years	No